stockholm 01-06-2005 - coloplast · switzerland croatia czech republic israel russia slovakia...
TRANSCRIPT
Coloplast A/SCarnegie Nordic Healthcare Seminar
31 May - 1 June
2
Coloplast
Coloplast products and services help patients achieve greater independence from medical challenges in 5 areas:
Ostomy care, continence care, wound care, skin care and breast care.
39%* 24% 12% 5% 7%
*Percentage of total group sales (2003/04)
3
0
1000
2000
3000
4000
5000
6000
7000
1957
1962
1967
1972
1977
1982
1987
1992
1997
2002
History of revenue growth 1957-2004m
DKK
Danish productionand sale through
distributors
Product divisionsand subsidiaries
Acquisitions
Forward integration
4
Sales and production world wide
Austria
BelgiumGermany
Great Britain
Italy
Sweden
Norway
Argentina
Australia
Brazil
Canada
USA
France
Holland
Hungary
Poland
Spain
Japan
Switzerland
Israel RussiaCzech Republic SloveniaSlovakiaCroatia South Africa
Denmark
Costa Rica
Portugal
China
5
Geographical distributionRevenue 2003/04
Europe The Americas ROW
81%
6%13%
6
Risk factors
1. Reimbursement policy changes2. Increased price pressure in the market from e.g.
• Consolidation of wholesalers (distribution monopolies)• Fewer and more powerful insurance companies• Increased group purchasing, tendering and managed health care
3. Harmonisation of health care systems in Europe resulting in decreasing prices in high-price countries
4. Escalation of parallel importing5. Market growth influenced by:
• Earlier cancer detection reduces need for radical surgery• Improved surgical procedures• Increased longevity• New technologies and treatment alternatives• Slowdown in conversion from older products
7
…that must be addressed appropriately
1. Reimbursement• Monitor/influence policy• Product design• Emphasis on clinical
documentation
2. Price pressure• Observe market trends• Improve tendering capabilities
3. Harmonisation of health care systems• Monitor development
4. Parallel imports• Monitor importers’ activities• Price strategy coordination• Product and packaging
diversification
5. Slowdown in market growth• Focus on growth segments• Search for new technologies• Low cost production
8
Three key customers
• The end customer• The user, primary concern
is quality of life• The health care professional
• The advisor, primary concerns are user qualityof life and handling
• The payer• Concern is primarily
product pricing
9
Competitor overview
Total corp.
% of total
Turn
over
by
busi
ness
are
a(D
KK
m)
Ostomy care
Continence care
Wound care
Skin care
ConvaTec
Hollister
Mentor
Astra Tec
h
S&N
J&J
Coloplast
4% 80%12%20%67% ½% ¼%
10
Business StructureGroup Management
Woundcare
Breastcare
Skinhealth
Ostomycare
Continencecare
Volume
production
Americas
Europe,South
Europe,North
RoW
Chronic care segment SBU segment
Corporate functions
Sales
11
Ostomy care - for discreet protection
• Normal function of bowel or bladder lost
• Almost 80% related to cancer
• Designed for security, skin-friendliness, discretion, ease of use and comfort
• Wide variety of bags, plugs and accessories
12
Ostomy care - competitorsGlobal market value DKK 8-8½bn
Europe (>4bn)
ConvaTec Coloplast Hollister B Braun Other
28%
37%
24%
5%6%
USA (<2bn)
56%
3%
39%
2%
Note: Only markets where Coloplast is present are included
35%
28%
27%
10%
Global (>8bn)
13
Continence care - for independent living
• Spinal cord injured, multiple sclerosis, spina bifida
• Discreet and easy-to-use solutions
• Catheters, urine bags, urisheaths, bowel management, absorbentproducts
14
Continence care - market data
No direct competitors--1.0bn DKK2%
>60%
30% (value)
43%
Coloplast marketshare (EU15)
Maincompetitors
Coloplastgrowth
Marketsize
Productarea
Mentor, Hollister, Rochester, Manfred Sauer
0-3%0.5bn DKK0-3%
Bard, Hollister, Mentor, B Braun, Manfred Sauer, Unomedical
5%1.2bn DKK0-5%
Astra Tech, Porges/Mentor,Rüsch, Rochester, B Braun
15-20%1.5bn DKK15%
15
Chronic care - US market positioning and key goals
• Strong product portfolio• Convex baseplate, EasiClose
• Market access through GPO/IDN• Consorta• Large number of IDN contracts
• Significant growth in new patient discharge• Sustained OC hospital growth > 30%
• Sustained OC/CC growth > 20%• Reach two-digit ostomy market share within 3-5 years• Develop intermittent coated catheter market segment
16
Coloplast home care activities
Leading provider in the US of ostomy, wound care, urological, and diabetic products and cost management services. Ownership since 2001.
Distribution of ostomy, continence care and wound care products in the UK. Cutting service for ostomists. Internal merger of Coloplast Direct (1996) and ThackrayCare(2001). Established 2004.
German market leader in active distribution. Distributing 1/3 of all ostomy bags in Germany. Ownership majority since 2001.
17
Effects of changing market conditions in Germany
Jan 05
Oct 04
Jul 0
4Apr 0
4Ja
n 04
CC draft fornew prices
OC finaldecision
CC final decisionpostponed
OC pricereduction
OC draft fornew prices
Implementation ofhealth care reform
Introduction ofpatients‘ co-paymentfor medical devices
Reimbursement onauxiliary productsremoved
CC final decision
Dec 04
Exp au
tumn 2005
Oct 03
Stockingby users,additionalsales
Mar
ket c
ondi
tions
Mar
ket e
ffect
s Retail anticipateslower prices,dampenedsales.Comparison with Q1 03/04
De-stockingby users,dampenedsales, higheradmin. costs
Alignment tochanged marketconditions
18
Wound care - providing better outcomes
• For difficult to heal wounds• leg ulcers, pressure sores,
diabetic ulcers• Primarily affects the elderly• Portfolio of advanced, active
dressings• Education, information
and service
19
€ 1.0 billion€ 1.0 billion
Wound care - market definition
Moistwound healing
Drywound healing
ChronicAcute
€ 0.5 billion
€ 1.0 billion€ 1.5 billion
Wound type
Pharma and biotech
VAC
€ 0.1 billion
€ 0.4 billion
Active
€ 0.4 billion
€ 0.1 billion
Prod
uct t
echn
olog
y
€ 1.1 billion segment, growth 9-11%
Compression
20
27%
17%14%
11%
21%
10%
Convatec S&NColoplast J&JMölnlycke Others
Wound care - market shares in EuropeMWH and active products
XXMölnlyckeXXXJ&JXXColoplastXXS&NXXConvaTec
ActiveAdvancedTraditionalTechnology
21
Growth H1 2004/05- local currencies
Continence care (24%)Ostomy care (39%)
Other (13%)
Wound care (12%)Breast care (7%)Skin health (5%)
*Includeshomecare
Est. market growth
GrowthQ1 2004/05
Growth H1 2004/05
4%8%
18%
5%10%23%
EuropeAmericasROW
5%7%Coloplast total
2-6%5-8%
9-11%9-12%
(3)-(1)%
13%8%6%4%
12%(3)%
4%
12%9%8%8%7%
(1)%5%
Ostomy careContinence careChronic care segment*Wound careSkin healthBreast careSBU segment
22
Key figures H1 2004/05
-87
1007884
-108
90106
Index vs2003/04
16%275
-2-152429
0-48
4772,924
6 months2003/04
14%240
-2-119361
-17-52
4303,099
6 months2004/05
EBIT
Profit marginGroup profitMinority interestsTaxProfit before tax
Special itemsFinancial items
RevenuemDKK
23
Profit and margins - how to reach 18%…
• Relocation- Hungary and China
• Efficiency projects / abc
• SBU margin improvement
• Economies of scale0
200
400
600
800
1000
1200
99/00 00/01 01/02 02/03 03/0410
11
12
13
14
15
16
17
EBIT EBIT %
mn %
24
Tatabanya, Hungary
• 550 headcounts by Sept. 2004• Construction completed• DKK 1.5bn sales value in 2005/06• Corporate tax rate 16%• Tax investment incentive
DKK 150mn
• Phase I - finalised: ostomy bags, urisheaths• Phase II - finalised: ostomy bags, dressings, catheters• Phase III - finalised 2005: Assura ostomy bags, baseplates, adhesives
Coloplast, Phase I-III, Tatabanya, Hungary
25
Expectations and targets
• Sales growth of 8-9% inlocal currencies
• Profit margin 15-16%
• Sales exceeding DKK 9 billionthrough organic growth
• Profit margin (EBIT) reaching 18%• ROAIC of 20%• Acquisitions and divestments
2004/05
2008
MAINTAINED
26